JP2016530283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530283A5 JP2016530283A5 JP2016539013A JP2016539013A JP2016530283A5 JP 2016530283 A5 JP2016530283 A5 JP 2016530283A5 JP 2016539013 A JP2016539013 A JP 2016539013A JP 2016539013 A JP2016539013 A JP 2016539013A JP 2016530283 A5 JP2016530283 A5 JP 2016530283A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- membered monocyclic
- optionally
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870371P | 2013-08-27 | 2013-08-27 | |
| US61/870,371 | 2013-08-27 | ||
| PCT/US2014/052600 WO2015031295A1 (en) | 2013-08-27 | 2014-08-26 | Ido inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530283A JP2016530283A (ja) | 2016-09-29 |
| JP2016530283A5 true JP2016530283A5 (OSRAM) | 2017-10-12 |
| JP6371851B2 JP6371851B2 (ja) | 2018-08-08 |
Family
ID=51539339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539013A Expired - Fee Related JP6371851B2 (ja) | 2013-08-27 | 2014-08-26 | Ｉｄｏ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9758492B2 (OSRAM) |
| EP (1) | EP3039020B1 (OSRAM) |
| JP (1) | JP6371851B2 (OSRAM) |
| CN (1) | CN105658643B (OSRAM) |
| CA (1) | CA2921199A1 (OSRAM) |
| EA (1) | EA029981B1 (OSRAM) |
| MX (1) | MX2016002075A (OSRAM) |
| WO (1) | WO2015031295A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675571B2 (en) * | 2013-03-15 | 2017-06-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (IDO) |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN105517999B (zh) * | 2013-07-11 | 2019-06-28 | 百时美施贵宝公司 | Ido抑制剂 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2016161279A1 (en) * | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| RU2018112749A (ru) * | 2015-09-24 | 2019-10-24 | ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед | Модуляторы индоламин-2,3-диоксигеназы |
| EP3416725A1 (en) | 2016-02-19 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| CN108884104B (zh) * | 2016-02-19 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| US10323004B2 (en) * | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2017192811A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10633342B2 (en) * | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10538495B2 (en) | 2016-05-12 | 2020-01-21 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN107556244B (zh) * | 2016-07-01 | 2021-09-03 | 上海迪诺医药科技有限公司 | 并环化合物、其药物组合物及应用 |
| CN109689652B (zh) * | 2016-08-23 | 2022-04-26 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| EP3503891A1 (en) | 2016-08-26 | 2019-07-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN108017639B (zh) * | 2016-11-01 | 2020-09-15 | 南京华威医药科技集团有限公司 | Ido抑制剂及其制备方法和应用 |
| ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| EP3570832A4 (en) | 2017-01-17 | 2020-06-10 | Board Of Regents, The University Of Texas System | NOVEL COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHANE DIOXYGENASE |
| JP7065951B2 (ja) | 2017-09-22 | 2022-05-12 | ジュビラント エピパッド エルエルシー | Ｐａｄ阻害剤としての複素環式化合物 |
| WO2019077631A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Biosys Limited | IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| WO2019136112A1 (en) * | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| EP3743063A4 (en) * | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| WO2019175897A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Biosys Limited | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023355A1 (en) * | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN111763164B (zh) * | 2019-04-02 | 2023-03-10 | 中国医学科学院药物研究所 | 一类邻位羰基氨基取代苯衍生物的制备方法和用途 |
| BR112021019722A2 (pt) | 2019-04-09 | 2021-12-14 | Nurix Therapeutics Inc | Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico |
| US20220339249A1 (en) | 2019-09-25 | 2022-10-27 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
| CN111153850B (zh) * | 2020-01-17 | 2021-08-13 | 中国药科大学 | 吲哚类化合物、其制备方法和药物组合物与用途 |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| JP7502564B2 (ja) * | 2020-11-06 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用 |
| CN112206228A (zh) * | 2020-11-24 | 2021-01-12 | 烟台大学 | 紫杉醇和ido1小分子抑制剂复方药物组合物及其用途 |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2022184930A2 (en) | 2021-03-05 | 2022-09-09 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| TW202337455A (zh) | 2021-12-09 | 2023-10-01 | 美商迪賽孚爾製藥有限公司 | Ｒａｆ激酶抑制劑及其使用方法 |
| CN120187710A (zh) * | 2023-09-28 | 2025-06-20 | 四川大学华西医院 | 一种含苯环的具有镇痛功效的化合物及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| EP1619184A3 (en) * | 2000-08-15 | 2006-02-01 | Amgen, Inc. | Urea compounds as kinase inhibitors |
| JP2003091058A (ja) * | 2001-09-19 | 2003-03-28 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| ATE323702T1 (de) * | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| CN1795187A (zh) * | 2003-03-27 | 2006-06-28 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
| WO2005121132A1 (ja) * | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| US7625931B2 (en) * | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
| CA2634198C (en) * | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20110098296A1 (en) * | 2007-12-13 | 2011-04-28 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
| WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| WO2010019930A1 (en) * | 2008-08-15 | 2010-02-18 | Locus Pharmaceuticals, Inc. | Urea derivatives as inhibitors of map kinases |
| US8722720B2 (en) * | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| JP6240063B2 (ja) * | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート， インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
-
2014
- 2014-08-26 CA CA2921199A patent/CA2921199A1/en not_active Abandoned
- 2014-08-26 MX MX2016002075A patent/MX2016002075A/es unknown
- 2014-08-26 CN CN201480058859.6A patent/CN105658643B/zh not_active Expired - Fee Related
- 2014-08-26 US US14/914,184 patent/US9758492B2/en active Active
- 2014-08-26 EA EA201690306A patent/EA029981B1/ru not_active IP Right Cessation
- 2014-08-26 JP JP2016539013A patent/JP6371851B2/ja not_active Expired - Fee Related
- 2014-08-26 WO PCT/US2014/052600 patent/WO2015031295A1/en not_active Ceased
- 2014-08-26 EP EP14766038.5A patent/EP3039020B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530283A5 (OSRAM) | ||
| JP2016523974A5 (OSRAM) | ||
| JP2016528197A5 (OSRAM) | ||
| JP2016519653A5 (OSRAM) | ||
| JP2016518324A5 (OSRAM) | ||
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| JP2018516238A5 (OSRAM) | ||
| JP2014518544A5 (OSRAM) | ||
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| JP2019529484A5 (OSRAM) | ||
| RU2016134751A (ru) | Соединения | |
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2015508103A5 (OSRAM) | ||
| JP2016513137A5 (OSRAM) | ||
| JP2018515438A5 (OSRAM) | ||
| JP2018524390A5 (OSRAM) | ||
| JP2018533611A5 (OSRAM) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2017504635A5 (OSRAM) | ||
| JP2016519078A5 (OSRAM) | ||
| CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
| JP2013510123A5 (OSRAM) |